BRD2 and neoplasm: Some investigators showed that the MP in RMACs is a key factor affecting the NAT efficacy (11, 13), and Cao et al. found that when the proportion of the MP is >62.1%, the tumor burden is relatively low, and this could be used as an independent factor in predicting the efficacy of NAT (14).